HCPLive Network
Latest Specialty Pharmacy Headlines
By Michael R. Page, PharmD, RPh
In a phase II trial, combination treatment with simeprevir and sofosbuvir yields functional cure rates exceeding 90% in patients receiving 12 weeks of therapy—even among difficult-to-treat patients.
By Davy James, Associate Editor
Study finds aspirin improves survival outcomes only for patients with HLA class I antigen expression.
By Davy James, Associate Editor
Celgene’s Abraxane is expected to drive expansion of pancreatic cancer therapeutics market.
By Michael R. Page, PharmD, RPh
The new design may potentially improve adherence and outcomes for patients with relapsing-remitting multiple sclerosis.
By Davy James, Associate Editor
Study suggests that standard dose of GnRH antagonist clears out of obese women’s systems more quickly than in normal-weight women.
By Michael R. Page, PharmD, RPh
Bristol-Myers Squibb submitted NDAs for daclatasvir and asunaprevir. Although asunaprevir is limited to treatment of genotype-1 HCV, a combination of daclatasvir with sofosbuvir may be useful in a range of HCV genotypes.
By Davy James, Associate Editor
Express Scripts Senior Clinical Consultant Aimee Tharaldson, PharmD, discusses specialty pharmacy treatment options for 2014 and beyond.
By Eileen Oldfield, Associate Editor
Patients with accelerated-phase chronic myeloid leukemia at diagnosis may benefit from immediate tyrosine kinase inhibitor therapy rather than alternate treatments.
By Davy James, Associate Editor
Efficacy of standard dose can be suboptimal in patients with hepatitis C, study shows.
Physician's Money Digest
Americans—regardless of age, income, and education—have proven to be pretty awful at handling their personal finances. Given the choice between saving and spending a sudden windfall, they’re more likely to spend the money.
Every time the top US tax rate increases by one percentage point, there is a more than 2% increase in US investors attempting to evade taxes by disguising themselves as foreign investors.
$AD300x250BB$